Hyperglycemia is one of the major causes for various types of diseases and clinical complications. 4-Morphionylphenyl-6-arylpyrimidine-2-imines (8a-k) are good sources of medicinal compounds, and are novelty used to control diabetes mellitus. In this study the compounds (8a-k) are investigated by the molecular docking analysis, in vitro enzyme inhibitory activity, and in vivo antihyperglycemic activity. The molecular docking results of compounds (8a-k) suggest one potential agent as 1v4s protein activators for future hyperglycemic therapeutics. The compounds (8a-k) show the significant inhibiting activity of the alpha-amylase enzyme at the concentration of (100 μg/ml) as compared to the alpha-glucosidase enzyme (100 μg/ml). The in vivo antihyperglycemic activity of compounds (8a-k) 10 mg/kg (po) against nicotinamide 120 mg/kg (po)-streptozotocin 60 mg/kg/b.w (ip)-induced diabetes in healthy adult male albino Wistar rats are estimated and the entire designed compounds (8a-k) exhibits significant antihyperglycemic activity. These results suggest that the compounds (8a-k) may be a potential source for the development of new oral antihyperglycemic agent.
Select your language of interest to view the total content in your interested language
Der Pharma Chemica received 15261 citations as per Google Scholar report